| Sign In to gain access to subscriptions and/or personal tools. |
Triple Therapy for Acute Deep ThrombophlebitisNortheast Cardiovascular Clinic and Research Institute, Wilkes-Barre, Pennsylvania Therapy for patients with extensive thrombophlebitis is often inadequate with available methods. The reluctance of most physicians in private practice to use streptokinase or urokinase is understandable when one considers the cost, hospitalization, length of stay and risks involved. This article discusses a unique and previously unreported mode of drug therapy in these patients, consisting of a combination of drugs designed to combine the antithrombotic and thrombus antipropagating effects of warfarin, the anti-inflammatory effect of trypsin-chy motrypsin enzymes, and the antiplatelet aggregating, antiadhesion, and pos sible enhanced fibrinolytic effects of aspirin with added buffered protection (Ascriptin A/D). This treatment program has been a safe, efficient, economical, and highly effective one for a very costly, common, and disabling disease. It therefore ful fills the ideal criteria for any form of therapy, provided one is knowledgable of its content, and adheres to its contraindications as well as to the basic appli cation of the drugs involved. It is hoped that further investigations along these lines will continue until an ideal solution is reached. Although this is a pre liminary report, this study will continue in its present form, and will be ex panded to include a series of patients on the aspirin-enzyme combination with out the use of warfarin.
Angiology, Vol. 31, No. 6,
398-409 (1980) This article has been cited by other articles:
|
|||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
